medscape.com
Planning Pregnancy in Crohn's: Expert Insights - Medscape
Pregnancy planning affects disease and pregnancy outcomes in Crohn’s. Staying in remission and maintaining needed IBD medications during pregnancy reduces risks to both mother and baby, while stopping certain drugs (notably methotrexate) is essential before conception.
Women with Crohn’s disease of childbearing age, partners and caregivers, gastroenterologists, obstetricians managing high-risk pregnancies, and IBD nurse coordinators.
What To Know
What to know This Medscape commentary summarizes expert guidance on pregnancy planning for people with Crohn’s disease, emphasizing preconception counseling, aiming for steroid-free remission before conception, and continuing needed medications during pregnancy to avoid risks from active disease.
The article reviews medication-specific recommendations: thiopurines (azathioprine, 6-mercaptopurine) are generally considered compatible with pregnancy but not usually started during pregnancy; methotrexate is an absolute contraindication and should be stopped ≥3 months before conception; biologic therapies are recommended to be continued when required to maintain remission.
It also highlights monitoring (liver tests with thiopurines, objective disease markers before conception) and references the PIANO registry and a 2025 global consensus statement. Practical points covered include counseling about contraception choices, fertility effects of pelvic surgery, and prioritizing remission before conception.
The piece frames preconception care as high-yield and encourages dedicated counseling from gastroenterology providers.
Recommendations are based on registry data (PIANO) and a 2025 global consensus statement; advice emphasizes individualized decision-making with clinicians. Some drug-specific monitoring (eg, liver tests with thiopurines) and timing for surgery or contraceptive choices are practical considerations.
